Lantern Pharma Inc.
LTRN
$1.77
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.77M | 6.63M | 6.46M | 6.63M | 6.18M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.47M | 16.61M | 17.98M | 19.67M | 20.50M |
| Operating Income | -15.47M | -16.61M | -17.98M | -19.67M | -20.50M |
| Income Before Tax | -18.65M | -15.91M | -17.12M | -18.92M | -19.25M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.65 | -15.91 | -17.12 | -18.92 | -19.25 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.65M | -15.91M | -17.12M | -18.92M | -19.25M |
| EBIT | -15.47M | -16.61M | -17.98M | -19.67M | -20.50M |
| EBITDA | -15.45M | -16.59M | -17.96M | -19.65M | -20.48M |
| EPS Basic | -1.61 | -1.44 | -1.57 | -1.75 | -1.78 |
| Normalized Basic EPS | -1.00 | -0.90 | -0.98 | -1.09 | -1.11 |
| EPS Diluted | -1.61 | -1.44 | -1.57 | -1.75 | -1.78 |
| Normalized Diluted EPS | -1.00 | -0.90 | -0.98 | -1.09 | -1.11 |
| Average Basic Shares Outstanding | 45.83M | 44.19M | 43.72M | 43.28M | 43.21M |
| Average Diluted Shares Outstanding | 45.83M | 44.19M | 43.72M | 43.28M | 43.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |